Most Recent
Noting the relevant three-year limitations provision was "quite unusal", the judge overseeing a consumer class action against horse vaccine manufacturer Zoetis has given the class a chance to add a second applicant to the case, after it was revealed that part of the lead applicant's claim was out of time.
Melbourne-based Carbone Lawyers has filed the first Australian lawsuit against agribusiness giant Monsanto linking the company's popular weedkiller RoundUp to cancer.
The Federal Court has granted Treasury Wine Estates costs of a stayed class action filed against it by a firm owned by solicitor Mark Elliott, despite a settlement in a related class action barring TWE from seeking remedies from class members.
NSW Ports is facing a new lawsuit over an allegedly anti-competitive agreement entered into with the NSW state government for the privatisation of Port Botany and Port Kembla, which is the subject of a separate case brought by the competition regulator.
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
The former chief financial officer of a unit of collapsed Gold Coast finance company Octaviar Investments is facing fraud charges for allegedly misappropriating more than $4.6 million in company funds for his personal use.
In its opening submissions in a trade mark case brought by Botox maker Allergan, Australian cosmetics brand Self Care compared its used of the word Botox to describe its alternative cosmetic products to the iPhone secondary accessories market, saying its use did not imply an affiliation with the injectable wrinkle treatment's maker.
A senior Piper Alderman partner who has launched a sex discrimination case against the law firm rejected “reasonable settlement offers” that would have allowed her to leave the partnership on a “dignified basis”, counsel for the firm has told a court.
A former finance manager from Hastie Services and key witness for the prosecution in the criminal trial against two of the company's former executives only pointed the finger at former COO Ian Thompson to avoid jail time herself, a jury has heard.
Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.